In yesterday’s Wall Street session, Mersana Therapeutics Inc (NASDAQ:MRSN) shares traded at $0.62, down -13.68% from the previous session.
MRSN stock price is now -68.38% away from the 50-day moving average and -72.05% away from the 200-day moving average. The market capitalization of the company currently stands at $76.77M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On March 19, 2024, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $5, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, Bala Mohan, SVP, Chief Development Officer sold 1,884 shares of the company’s stock on Oct 28 ’24. The stock was sold for $3,580 at an average price of $1.90. Upon completion of the transaction, the SVP, Chief Development Officer now directly owns 54,731 shares in the company, valued at $33933.22. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 28 ’24, Officer Bala, Mohan bought 1,884 shares of the business’s stock. A total of $3,843 was incurred on buying the stock at an average price of $2.04. A total of 29.93% of the company’s stock is owned by insiders.
During the past 12 months, Mersana Therapeutics Inc has had a low of $0.69 and a high of $6.28. As of last week, the company has a debt-to-equity ratio of 30.00, a current ratio of 2.35, and a quick ratio of 2.35. The fifty day moving average price for MRSN is $1.9918 and a two-hundred day moving average price translates $2.2417 for the stock.
The latest earnings results from Mersana Therapeutics Inc (NASDAQ: MRSN) was released for 2024-09-30. The net profit margin was -214.19% and return on equity was -280.29% for MRSN. The company reported revenue of $12.6 million for the quarter, compared to $7.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 63.65 percent.